ArticleFrontiers in endocrinology2026
Ultrasound-guided radiofrequency ablation for recurrent contralateral tumors that developed after initial surgery for papillary thyroid carcinoma.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to investigate the efficacy and safety of ultrasound-guided radiofrequency ablation (RFA) for recurrent contralateral tumors that developed after initial surgery for papillary thyroid carcinoma (PTC). Methods: This retrospective study included 32 postoperative patients with PTC with unifocal recurrent contralateral tumors who underwent RFA between January 2015 and December 2021. The RFA procedures were performed using the hydrodissection technique, moving-shot technique, and enlarged ablation technique. Patients were followed up at 1, 3, 6, 12 months, and every 12 months thereafter. Local tumor progression (LTP), volume reduction rate (VRR), tumor complete disappearance, complications, and delayed surgery were evaluated during the follow-up. Results: The mean follow-up period of RFA was 54.4 ± 24.3 months. Two patients developed lymph node metastases (LNMs), and the overall incidence of LTP was 6.3% (2/32). No newly identified tumors or distant metastases were observed. The median VRR was 100%, and 90.4% of the tumors had completely disappeared. One patient experienced transient voice change (3.1%). Because of anxiety, one patient underwent delayed surgery (3.1%), and no residual cancer cells, occult tumors, or cervical LNMs were found. No patients experienced hypothyroidism following RFA. Conclusions: RFA may be considered as a feasible and safe local treatment for recurrent contralateral tumors after the initial surgery for PTC in select patients who are not candidates for or who refuse repeat surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.